Elutia Inc Class A (ELUT)

Elutia's stock price has fluctuated significantly in the past six months, reaching a 52-week high of $3.46 and a low of $0.50. As of January 15, 2026, ELUT was priced at $1.78 per share after a 5.82% drop. Key events include a reported net loss of $54 million for fiscal year 2024, Q3 revenue reported at $332.3 million, the sale of its BioEnvelope business to Boston Scientific Corporation for $88 million, preliminary fourth-quarter 2025 results showed a 16% year-over-year revenue increase, elimination of $26.9 million in secured debt, and total cash and escrowed proceeds of $44.3 million at year-end. Insider trading activity has shown confidence, with insiders buying more company stock than they have sold in the past three months, specifically $220,810.00 in purchases and $0.00 in sales.

Information regarding the specific demand seasonality for Elutia, Inc.'s products and services is not publicly available in the provided search results. Some sources indicate that data on market seasonality can be accessed by creating an account.

Elutia, Inc., formerly Aziyo Biologics, Inc., is a regenerative medicine company focused on drug-eluting biologics within the Healthcare sector and Medical Devices industry. The company aims to improve medical device compatibility with patients to promote tissue formation and prevent complications. Elutia's business is segmented into Device Protection, Women's Health, and Cardiovascular, with Women's Health generating the most revenue. Key products include EluPro and CanGaroo for device protection, ProxiCor for cardiac tissue repair, Tyke for repairing cardiac structures in neonates and infants, VasCure for repairing peripheral vasculature, and SimpliDerm for tissue repair and reconstruction.

Elutia, Inc. develops and commercializes its products primarily in the United States. The company serves hospitals and healthcare facilities through its direct sales force, commercial partners, independent sales agents, and distributors. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.

Elutia's brand reputation shows a "Hold" consensus rating with an average score of 2.33, based on two buy ratings and one sell rating. Some analysts have a "Strong Buy" consensus rating with a 12-month price target of $7.00. Investor sentiment has improved, with short interest decreasing by 7.14%. Events affecting Elutia's reputation include a net loss for fiscal year 2024, the sale of its BioEnvelope business, and positive preliminary fourth-quarter 2025 results. The company's focus on pioneering drug-eluting biomatrix technologies and its mission to humanize medicine also contribute to its brand identity.

Elutia Inc. has 41 institutional owners and shareholders, holding a total of 18,169,981 shares. Approximately 74.03% of Elutia's stock is held by institutions, while 27.60% is held by insiders. Major institutional shareholders include Nantahala Capital Management, LLC, AIGH Capital Management LLC, Silverarc Capital Management, Llc, Alyeska Investment Group, L.P., Deerfield Management Company, L.p. (series C), Vanguard Group Inc, Perkins Capital Management Inc, Knollwood Investment Advisory, LLC, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares and Birchview Capital, LP. Individual insider transactions in late 2025 and early 2026 show several directors and officers purchasing shares.